A dossier filed in English still needs 39 Module 3 sections in Russian. Which documents can be submitted without translation


If a registration dossier is submitted in English, 39 sections of Module 3 (the part of the dossier on the quality of the medicinal product) must be translated into Russian, while the other documents of Modules 3-5 may be submitted in English. This is established by the Rules for Registration and Regulatory Review of Medicines for Medical Use, approved by Decision of the Council of the Eurasian Economic Commission (EEC) No. 78 of 3 November 2016 (hereinafter the Registration Rules).
After registration, other acts determine the language of documents. The registration holder submits adverse reaction descriptions and the periodic safety update report (hereinafter PSUR) under the Good Pharmacovigilance Practice Rules, and prepares the package leaflet under the Requirements for the Instructions for Medical Use.

Which EEC acts establish the language of documents

The language of the registration dossier is determined by the Registration Rules. The language of the package leaflet and the summary of product characteristics (hereinafter SmPC) is determined by the Requirements for the Instructions for Medical Use of a Medicinal Product and the Summary of Product Characteristics of a Medicinal Product for Medical Use, approved by Decision of the EEC Council No. 88 of 3 November 2016 (hereinafter Requirements No. 88). The language of safety reports and reports of adverse reactions is determined by the Good Pharmacovigilance Practice Rules, approved by Decision of the EEC Council No. 87 of 3 November 2016 (hereinafter the GVP Rules).
The Good Manufacturing Practice Rules, approved by Decision of the EEC Council No. 77 of 3 November 2016 (hereinafter the GMP Rules), name a language only for products used in clinical trials: the data on their labeling are stated in the official language of the country of use, and other languages are permitted. The GMP Rules contain no requirements on the language or translation of standard operating procedures.
Recommendation of the EEC Board No. 25 of 19 September 2023 «On the Guideline on Ensuring Data Integrity and Validation of Computerized Systems» contains no provisions on the language or translation of documents.

What language registration dossier documents are submitted in

Registration dossier documents are submitted in Russian or with a Russian translation. The Registration Rules refer to an approximate list of documents submitted in the dossier modules for different types of medicinal products, but that list was removed by Decision of the EEC Council No. 60 of 22 May 2023.
English is permitted for four groups of documents: the document in Section 1.6.3 of Module 1 (reports of inspections for compliance with GMP, and the plan and report on corrective and preventive actions), the documents of Modules 3-5, the pharmacovigilance system master file, and the risk management plan (hereinafter RMP). Of these, 39 sections of Module 3, the summary of the registration holder’s pharmacovigilance system and the RMP summary are translated into Russian. Module 2 (summaries and overviews) is not named in this list.
An exception is made for a medicinal product registered in one member state and intended for circulation only in its territory: the applicant may submit Modules 1-3 in the official language of that state, or in another language if its legislation so provides, without a Russian translation. The condition is that Russian is not considered an official language in that member state. Applications for dossier alignment with Union requirements were accepted until 31 December 2025.
The Registration Rules establish language requirements for individual documents (Table 1).

Table 1. Language requirements for individual dossier documents

DocumentLanguage requirement
Assessment report issued by an authority of the country of manufacture or of the registration holder’s country (if available)A Russian translation and a copy certified in the established manner; submission of this information is optional for dossier alignment with Union requirements
Draft SmPC and instructions for medical use (package leaflet)In Russian
Letter from the active pharmaceutical ingredient master file holder on the undertaking to report changesTranslation of the letter certified by the registration holder or by a notary
Letter from the Qualified Person for qualityWith a Russian translation where necessary
Copy of a monograph from the pharmacopoeia of another stateTranslation where necessary
Document in Section 1.6.3 of Module 1 (GMP inspection report, corrective and preventive action plan and report)English is permitted
Pharmacovigilance system master fileEnglish is permitted
Summary of the registration holder’s pharmacovigilance systemTranslated into Russian
Risk management plan (RMP)English is permitted; the RMP summary is translated into Russian
Documents of Modules 3-5English is permitted; translation of 39 sections of Module 3 is mandatory (Table 2)

The Registration Rules mention certification of the translation itself only for the master file holder’s letter: the translation is certified by the registration holder or by a notary. For the assessment report, the copy is certified.

Which Module 3 sections are translated if the dossier is submitted in English

The Registration Rules name 39 sections of Module 3 (Table 2). The list is closed: sections of Modules 3-5 outside it may remain in English.

Table 2. The 39 sections of Module 3 translated into Russian

No.SectionContent
13.2.S.2.2Description of manufacturing process and process controls (drug substance)
23.2.S.2.4Controls of critical steps and intermediates (drug substance)
33.2.S.2.5Process validation and/or evaluation (drug substance)
43.2.S.3.1Elucidation of structure and other characteristics
53.2.S.3.2Impurities
63.2.S.4.1Specification (drug substance)
73.2.S.4.2Analytical procedures (drug substance)
83.2.S.4.3Validation of analytical procedures (drug substance)
93.2.S.4.5Justification of specification (drug substance)
103.2.S.6Container closure system (drug substance)
113.2.S.7.1Stability summary and conclusions (drug substance)
123.2.P.1Description and composition of the medicinal product
133.2.P.2.1.1Active pharmaceutical ingredient
143.2.P.2.1.2Excipients
153.2.P.2.2.1Formulation development
163.2.P.2.2.2Overages
173.2.P.2.2.3Physicochemical and biological properties
183.2.P.2.3Manufacturing process development
193.2.P.2.4Container closure system (drug product)
203.2.P.2.5Microbiological attributes
213.2.P.2.6Compatibility
223.2.P.3.3Description of manufacturing process and process controls (drug product)
233.2.P.3.4Controls of critical steps and intermediates (drug product)
243.2.P.3.5Process validation and/or evaluation (drug product)
253.2.P.4.3Validation of analytical procedures (excipients)
263.2.P.4.4Justification of specifications (excipients)
273.2.P.4.5Excipients of human or animal origin
283.2.P.4.6Novel excipients
293.2.P.5.1Specifications (drug product)
303.2.P.5.2Analytical procedures (drug product)
313.2.P.5.3Validation of analytical procedures (drug product)
323.2.P.5.5Characterization of impurities
333.2.P.5.6Justification of specifications (drug product)
343.2.P.7Container closure system (drug product)
353.2.P.8.1Stability summary and conclusions (drug product)
363.2.P.8.2Post-approval stability protocol and stability commitment
373.2.A.2Adventitious agents safety evaluation
383.2.A.3Novel excipients
393.2.R.2Manufacturing process validation plan

Sections 3.2.S.4.4 («Batch analyses») and 3.2.P.5.4 («Batch analysis results») are not named in the list.

Language and terminology of the package leaflet and SmPC

Draft SmPCs and package leaflets are submitted in Russian. The informational content of the package leaflet cannot be identical to the SmPC and requires translation into the official language; translation into other languages is permitted if the text is identical. Only the package leaflet in the official language is subject to approval, and the Russian version agreed by the authorities of all states in which the medicinal product is registered is subject to expert assessment (Requirements No. 88).
The package leaflet must be understandable to patients and readable in the official languages; several languages are permitted if the text is complete in each of them. User testing (checking by patients that the package leaflet is understandable) is permitted in any language of the member states if the text is identical. When the package leaflet is translated into the official language, the expert organization may request a focus group study or bridging, that is, a reference to the testing results of a closely related parent package leaflet (Requirements No. 88).
When changes are made to the SmPC and package leaflet of a generic, hybrid or biosimilar medicine, the registration holder submits the current SmPC and package leaflet of the original (reference) medicinal product in the official language of the state in which they were approved, with a Russian translation (Requirements No. 88).

Terminology in the SmPC is fixed by Union acts:
1. The dosage form is written using the full standard term of the Union Pharmacopoeia (Decision of the EEC Board No. 100 of 11 August 2020). If no suitable term exists, a new term is formed from standard terms under the Nomenclature of Dosage Forms (Decision of the EEC Board No. 172 of 22 December 2015); if that is impossible, the applicant sends a request to the authorized body of a member state to have the Pharmacopoeial Committee of the Union introduce a new standard term (Requirements No. 88). The texts of the Union Pharmacopoeia are published in Russian and are official in that form (Decision of the EEC Board No. 100).
2. Adverse reactions in the SmPC are grouped by System Organ Class (SOC) of the Medical Dictionary for Regulatory Activities (MedDRA) and, within a class, by frequency, from «very common» to «frequency not known» (Requirements No. 88).
3. A reaction is described by a Preferred Term; lowest level terms and grouping terms are also permitted. The names of grouping terms can be adapted to make them clearer to the reader. The abbreviations NEC (not elsewhere classified) and NOS (not otherwise specified) cannot be used in the SmPC. The word order must be natural for medical terminology: «interstitial pneumonia», not «pneumonia interstitial» (Requirements No. 88).
4. Terms may be modified slightly, and for a condition the most widely used term is chosen: «Churg-Strauss syndrome» instead of «allergic granulomatous angiitis» (Requirements No. 88).

Which documents are translated after the dossier is submitted

The primary source’s initial description of an adverse reaction and the brief description are submitted in Russian (or with a Russian translation) when the reaction was identified in the territory of member states, and in English when it was identified in the territory of other states (GVP Rules). The translation of the individual case report into Russian, the supporting documents and the publications cited in the report are submitted at the request of the authorized body in the «Attached documents» section of the E2B electronic data format (GVP Rules).
The PSUR is submitted in Russian or English with mandatory translation of three sections: the executive summary, the integrated benefit-risk analysis for approved indications, and the conclusion. The registration holder translates the remaining sections at the request of the authorized body of a member state within 30 calendar days from the date the request is received (GVP Rules).
Information on a non-interventional post-registration safety study is submitted in Russian (preferably). If the protocol is written in English, the registration holder translates the study title, the protocol summary and the final report summary (GVP Rules).
Changes to the registration dossier are made under the procedure established by the Registration Rules. Documents from the list given in that procedure that are in a language other than Russian are submitted with an authentic Russian translation. The term «authentic translation» appears in the Registration Rules once, in this provision; the act has no definition of the term.

What happens if a translation is missing or inaccurate

The assessment of the completeness and full set of the documents and of the correctness of their execution takes 10 working days from the date of the application. The applicant is then given no more than 90 working days for the missing materials, and this time is not included in the registration and regulatory review period. The assessment of the applicant’s response takes no more than 5 working days.
The Registration Rules set the further procedure:
The authority rejects the application if the dossier materials on the comments are not submitted.
During the regulatory review, the expert organization may send a request for missing information and clarifications.
The response is given no later than 90 working days from the date the request is received.
The period can be extended if the applicant justifies it, but the total period for responses to requests does not exceed 180 working days.
The time for the response is not included in the regulatory review and registration period.
If the requested documents and information are not submitted on time, the regulatory review and registration are terminated, and the authority notifies the applicant of this within 14 working days.

Non-submission of the requested documents on time is named as a ground for refusing registration.
Other grounds for refusing registration based on the results of the regulatory review are an unfavorable benefit-risk balance, unconfirmed efficacy and quality, non-reproducible methods, unreliable information, and unconfirmed compliance with the good pharmaceutical practices of the Union based on the results of an inspection. Translation is not named in the provisions on missing materials, requests and grounds for refusal.
A translation error changes the meaning of the translated section. The examples in Table 3 are hypothetical and do not describe decisions of authorities.

Table 3. Hypothetical examples of translation errors in texts that must be translated

Translated materialErrorConsequence
Specification (Section 3.2.S.4.1, 3.2.P.5.1)The unit «ppm» is replaced with «%»The impurity limit in the Russian specification differs from the English one by a factor of 10,000 (1% equals 10,000 ppm)
SmPC, Section 4.3 «Contraindications»A contraindication is translated as a precaution (Section 4.4 «Special warnings and precautions for use»)The doctor reads a prohibition as permitted use with caution
Description of clinical data in the SmPC«Progression-free survival» is replaced with «overall survival»The claimed effect relates to a different endpoint

How to choose a translation provider

The Registration Rules, Requirements No. 88, the GVP Rules and the GMP Rules contain no requirements for the qualifications of a translator or a translation agency and do not establish a check of the translation by a second specialist. The applicant sets the criteria for choosing a provider.
The international standard ISO 17100:2015 («Translation services. Requirements for translation services») sets requirements for the core processes and resources of a written translation service and allows a translation provider to confirm conformity. It does not apply to interpreting or to the use of raw machine translation with post-editing (correction of the result of machine translation by a human).
ISO 18587:2017 («Translation services. Post-editing of machine translation output. Requirements», published on 12 April 2017) sets requirements for the process of full post-editing and for the competencies of the post-editor. The catalog gives it the status «to be revised» (stage 90.92 of 30 October 2023).
These standards are not part of Union law: EEC acts do not refer to them, and they become binding on a provider only if the applicant includes a reference to them in the contract. The full texts of the standards are paid, and their scope is described from standards catalogs.
The applicant may include in the contract with the provider a glossary of terms (names of dosage forms under the Union Pharmacopoeia, MedDRA terms in Russian), a check of the translation by a second specialist, and translation deadlines aligned with the deadlines for responding to comments and requests of the expert organization under the Registration Rules.

What to do

Determine the language in which the dossier is submitted and which documents are included in the translation. If the dossier is submitted in English, draw up a list of the 39 sections of Module 3 from Table 2 and check that it does not include Sections 3.2.S.4.4 and 3.2.P.5.4.
Check individual documents. The assessment report needs a translation and a certified copy, the master file holder’s letter needs a translation certified by the registration holder or by a notary, and draft SmPCs and package leaflets need Russian.
Prepare a glossary before the translation starts. Include the standard terms of dosage forms under the Union Pharmacopoeia and MedDRA terms for the sections on adverse reactions.
Take the deadlines of the Registration Rules into account in the translation schedule: 10 working days for the assessment of the completeness of the dossier and no more than 90 working days for missing materials, 90 working days to respond to a request and no more than 180 working days in total.
After registration, keep a separate list of pharmacovigilance documents whose language is set by the GVP Rules: descriptions of adverse reactions, three PSUR sections, and the title and summaries of a non-interventional study. If the authority requests translation of the remaining PSUR sections, it is submitted within 30 calendar days.

Regulatory framework

1. Decision of the EEC Council No. 78 of 3 November 2016 «On the Rules for Registration and Regulatory Review of Medicines for Medical Use» (as amended on 26 November 2025).
2. Decision of the EEC Council No. 88 of 3 November 2016 «On Approval of the Requirements for the Instructions for Medical Use of a Medicinal Product and the Summary of Product Characteristics of a Medicinal Product for Medical Use» (as amended on 21 February 2025).
3. Decision of the EEC Council No. 87 of 3 November 2016 «On Approval of the Good Pharmacovigilance Practice Rules of the Eurasian Economic Union» (as amended on 19 May 2022).
4. Decision of the EEC Council No. 77 of 3 November 2016 «On Approval of the Good Manufacturing Practice Rules of the Eurasian Economic Union» (as amended on 4 July 2023).
5. Decision of the EEC Board No. 100 of 11 August 2020 «On the Pharmacopoeia of the Eurasian Economic Union» (as amended on 25 June 2024).
6. Decision of the EEC Board No. 172 of 22 December 2015 «On Approval of the Nomenclature of Dosage Forms» (as amended on 21 November 2023).
7. Recommendation of the EEC Board No. 25 of 19 September 2023 «On the Guideline on Ensuring Data Integrity and Validation of Computerized Systems».
8. Decision of the EEC Council No. 60 of 22 May 2023 (title to be confirmed).

This page in Russian→